LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 25 of 66
Next
>>
>
601 to 625 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Alpelisib	180619_MC_12	14262	0.0280	112	291	5	18	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_7	403	0.0275	635.9	71.1	15071	356.7	0.0231	0.00441	0.9760
Alpelisib	180619_MC_12	14687	0.0255	116	261	7	14	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_8	377	0.0250	635.9	71.1	15071	356.7	0.0231	0.00195	0.9887
Alpelisib	180619_MC_12	14400	0.0258	119	256	9	15	Alpelisib	0.033266667	treatment	72	2	MCF10A-GM_9	375	0.0254	635.9	71.1	15071	356.7	0.0231	0.00231	0.9802
Alpelisib	180619_MC_10	12493	0.0244	68	238	3	7	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_1	306	0.0239	635.9	71.1	15071	356.7	0.0231	0.00083	0.9195
Alpelisib	180619_MC_10	12455	0.0248	70	240	9	3	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_2	310	0.0243	635.9	71.1	15071	356.7	0.0231	0.00121	0.9182
Alpelisib	180619_MC_10	13361	0.0190	54	201	10	18	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_3	255	0.0187	635.9	71.1	15071	356.7	0.0231	-0.00435	0.9479
Alpelisib	180619_MC_11	13922	0.0212	60	237	8	8	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_4	297	0.0209	635.9	71.1	15071	356.7	0.0231	-0.00219	0.9656
Alpelisib	180619_MC_11	12955	0.0226	75	219	9	4	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_5	294	0.0222	635.9	71.1	15071	356.7	0.0231	-0.00088	0.9348
Alpelisib	180619_MC_11	13518	0.0192	55	205	12	21	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_6	260	0.0189	635.9	71.1	15071	356.7	0.0231	-0.00420	0.9529
Alpelisib	180619_MC_12	14298	0.0299	141	291	3	15	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_7	432	0.0293	635.9	71.1	15071	356.7	0.0231	0.00625	0.9771
Alpelisib	180619_MC_12	12853	0.0304	118	276	5	3	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_8	394	0.0297	635.9	71.1	15071	356.7	0.0231	0.00667	0.9315
Alpelisib	180619_MC_12	13344	0.0213	80	206	6	5	Alpelisib	0.099799999	treatment	72	2	MCF10A-GM_9	286	0.0210	635.9	71.1	15071	356.7	0.0231	-0.00209	0.9474
Alpelisib	180619_MC_10	10838	0.0276	85	216	5	20	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_1	301	0.0270	635.9	71.1	15071	356.7	0.0231	0.00395	0.8607
Alpelisib	180619_MC_10	11649	0.0196	50	179	11	22	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_2	229	0.0193	635.9	71.1	15071	356.7	0.0231	-0.00379	0.8903
Alpelisib	180619_MC_10	11265	0.0194	51	168	12	6	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_3	219	0.0191	635.9	71.1	15071	356.7	0.0231	-0.00400	0.8765
Alpelisib	180619_MC_11	9376	0.0291	108	168	3	3	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_4	276	0.0286	635.9	71.1	15071	356.7	0.0231	0.00552	0.8026
Alpelisib	180619_MC_11	12320	0.0215	93	174	3	4	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_5	267	0.0212	635.9	71.1	15071	356.7	0.0231	-0.00186	0.9137
Alpelisib	180619_MC_11	11277	0.0253	55	232	6	17	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_6	287	0.0248	635.9	71.1	15071	356.7	0.0231	0.00174	0.8769
Alpelisib	180619_MC_12	12636	0.0250	99	220	4	14	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_7	319	0.0246	635.9	71.1	15071	356.7	0.0231	0.00155	0.9243
Alpelisib	180619_MC_12	11792	0.0169	71	130	6	12	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_8	201	0.0168	635.9	71.1	15071	356.7	0.0231	-0.00631	0.8954
Alpelisib	180619_MC_12	11466	0.0224	70	188	12	22	Alpelisib	0.316033316	treatment	72	2	MCF10A-GM_9	258	0.0220	635.9	71.1	15071	356.7	0.0231	-0.00107	0.8838
Alpelisib	180619_MC_10	8445	0.0248	73	138	5	3	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_1	211	0.0244	635.9	71.1	15071	356.7	0.0231	0.00130	0.7618
Alpelisib	180619_MC_10	8692	0.0262	57	172	6	5	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_2	229	0.0257	635.9	71.1	15071	356.7	0.0231	0.00260	0.7729
Alpelisib	180619_MC_10	9282	0.0193	30	150	12	11	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_3	180	0.0190	635.9	71.1	15071	356.7	0.0231	-0.00405	0.7986
Alpelisib	180619_MC_11	9059	0.0194	51	126	4	9	Alpelisib	0.997999808	treatment	72	2	MCF10A-GM_4	177	0.0192	635.9	71.1	15071	356.7	0.0231	-0.00391	0.7891

|<
<<
Previous
Page 25 of 66
Next
>>
>
601 to 625 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)